As it eyes its next funding round, the management software company Databricks is aiming to net a valuation of up to $175 billion. Last week, Ali Ghodsi, the startup’s co-founder and CEO, said that ...

June 8 (Reuters) - Data analytics software firm Databricks has discussed raising funds in a round that could begin next month and value it ‌at between $165 billion and $175 billion, The Information ...

The companies at the frontier of artificial intelligence should be ready to slow down, one of the fastest-moving among them says. Anthropic, the maker of the Claude chatbot, has claimed AI systems may ...

RSI is also defined as an “AI system capable of fully autonomously designing and developing its own successor,” per Anthropic’s blog post. “We are not there yet, and recursive self-improvement is not ...

Databricks, a data software company, plans to sell shares to the public at some point, but won’t tap the public markets this year amid a flurry of planned tech IPOs. The company wants to sell shares ...

Recursion is building an industrialized engine for medicine. It operates among biotech stocks, selling access to its proprietary platform and pursuing joint development with major partners like Roche ...

Claude Lemieux’s brain is being donated to the Boston University CTE Center to research the long-term effects of repetitive brain injuries, his family said Saturday in a statement released by daughter ...

The family of 21-year NHL veteran Claude Lemieux is donating his brain to CTE research. The family announced in a statement that the four-time Stanley Cup champion's brain will be given to the UNITE ...

"No conclusions should be drawn at this time regarding any diagnosis," the family said in a statement. Claude Lemieux died this week at age 60. Michael Martin / NHLI via Getty Images Claude Lemieux’s ...

EDITOR’S NOTE: This story contains discussion of suicide. Claude Lemieux’s brain is being donated to the Boston University CTE Center to research the long-term effects of repetitive brain injuries, ...

Recursion Pharmaceuticals is trying to solve a serious problem. Even with technological improvements, the time and costs required to develop brand-new drugs have increased in recent decades. It can ...

Arsalan Tavakoli was at his bachelor party in 2013 when Ali Ghodsi, a computer science researcher at the University of California, Berkeley, pulled him aside. The two had become colleagues and friends ...